Status:
COMPLETED
Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Nicotine Dependence
Tobacco Dependence
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
In this study we, the investigators at the Centre for Addiction and Mental Health, intend to explore whether bupropion is able to reduce smokers' responses to cigarette-related environmental cues, and...
Detailed Description
Current smoking cessation pharmacotherapy paradigms ignore the over-learned behaviour associated with smoking, thus contributing to the relatively poor absolute efficacy of pharmacotherapy. Chronic ni...
Eligibility Criteria
Inclusion
- Males or females
- At least 19 years of age
- Smoking at least 10 cigarettes per day for at least 2 years
- Never treated with bupropion/Zyban
Exclusion
- Co-morbid psychiatric disorder
- History of psychotic disorder or eating disorder
- Current alcohol or substance abuse/dependence (excluding nicotine, caffeine)
- Brain injury
- Seizure disorder
- Pregnancy, lactation, or at risk of becoming pregnant
- Current regular use of psychotropic drugs
- Known allergy or sensitivity to bupropion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00133757
Start Date
June 1 2005
End Date
May 1 2006
Last Update
February 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5S 2S1